298 related articles for article (PubMed ID: 26690047)
1. Analytical advances in pharmaceutical impurity profiling.
Holm R; Elder DP
Eur J Pharm Sci; 2016 May; 87():118-35. PubMed ID: 26690047
[TBL] [Abstract][Full Text] [Related]
2. Development of Impurity Profiling Methods Using Modern Analytical Techniques.
Ramachandra B
Crit Rev Anal Chem; 2017 Jan; 47(1):24-36. PubMed ID: 27070830
[TBL] [Abstract][Full Text] [Related]
3. Analytical methods for residual solvents determination in pharmaceutical products.
Grodowska K; Parczewski A
Acta Pol Pharm; 2010; 67(1):13-26. PubMed ID: 20210075
[TBL] [Abstract][Full Text] [Related]
4. Impurities in Oligonucleotide Drug Substances and Drug Products.
Capaldi D; Teasdale A; Henry S; Akhtar N; den Besten C; Gao-Sheridan S; Kretschmer M; Sharpe N; Andrews B; Burm B; Foy J
Nucleic Acid Ther; 2017 Dec; 27(6):309-322. PubMed ID: 29125795
[TBL] [Abstract][Full Text] [Related]
5. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
Liu DQ; Chen TK; McGuire MA; Kord AS
J Pharm Biomed Anal; 2009 Sep; 50(2):144-50. PubMed ID: 19427156
[TBL] [Abstract][Full Text] [Related]
6. Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping.
Li Y; Liu DQ; Yang S; Sudini R; McGuire MA; Bhanushali DS; Kord AS
J Pharm Biomed Anal; 2010 Aug; 52(4):493-507. PubMed ID: 20189340
[TBL] [Abstract][Full Text] [Related]
7. Strategies for the investigation and control of process-related impurities in drug substances.
Argentine MD; Owens PK; Olsen BA
Adv Drug Deliv Rev; 2007 Jan; 59(1):12-28. PubMed ID: 17189658
[TBL] [Abstract][Full Text] [Related]
8. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
9. An Overview of Advances in the Chromatography of Drugs Impurity Profiling.
ALSaeedy M; Al-Adhreai A; Öncü-Kaya EM; Şener E
Crit Rev Anal Chem; 2023; 53(7):1455-1471. PubMed ID: 35180027
[TBL] [Abstract][Full Text] [Related]
10. Assessment of Extractable Elements from Elastomers.
Paskiet D; Kraft C; Tullo E; Hunter J; Zurbriggen D
PDA J Pharm Sci Technol; 2019; 73(1):83-91. PubMed ID: 30030347
[TBL] [Abstract][Full Text] [Related]
11. Identification of pharmaceutical impurities in formulated dosage forms.
Pan C; Liu F; Motto M
J Pharm Sci; 2011 Apr; 100(4):1228-59. PubMed ID: 24081463
[TBL] [Abstract][Full Text] [Related]
12. Eliminating pharmaceutical impurities: Recent advances in detection techniques.
Liu DQ; Sun M; Wu L
Curr Opin Drug Discov Devel; 2010; 13(6):748-57. PubMed ID: 21061235
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical impurities and degradation products: uses and applications of NMR techniques.
Maggio RM; Calvo NL; Vignaduzzo SE; Kaufman TS
J Pharm Biomed Anal; 2014 Dec; 101():102-22. PubMed ID: 24853620
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in trace analysis of pharmaceutical genotoxic impurities.
Liu DQ; Sun M; Kord AS
J Pharm Biomed Anal; 2010 Apr; 51(5):999-1014. PubMed ID: 20022442
[TBL] [Abstract][Full Text] [Related]
15. Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.
Wu Y; Levons J; Narang AS; Raghavan K; Rao VM
AAPS PharmSciTech; 2011 Dec; 12(4):1248-63. PubMed ID: 21948318
[TBL] [Abstract][Full Text] [Related]
16. Analytical approaches for the detection of epoxides and hydroperoxides in active pharmaceutical ingredients, drug products and herbals.
Elder DP; Snodin D; Teasdale A
J Pharm Biomed Anal; 2010 Apr; 51(5):1015-23. PubMed ID: 20031361
[TBL] [Abstract][Full Text] [Related]
17. Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products.
Pokar D; Rajput N; Sengupta P
Int J Pharm; 2020 Feb; 576():119018. PubMed ID: 31911117
[TBL] [Abstract][Full Text] [Related]
18. Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review.
Reddy AV; Jaafar J; Umar K; Majid ZA; Aris AB; Talib J; Madhavi G
J Sep Sci; 2015 Mar; 38(5):764-79. PubMed ID: 25556762
[TBL] [Abstract][Full Text] [Related]
19. International Conference on Harmonisation; revised guidance on Q3B(R) Impurities in New Drug Products; Availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2003 Nov; 68(220):64628-9. PubMed ID: 14619944
[TBL] [Abstract][Full Text] [Related]
20. Impurities in drug substances and drug products: new approaches to quantification and qualification.
Berridge JC
J Pharm Biomed Anal; 1995 Dec; 14(1-2):7-12. PubMed ID: 8833961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
